when do compounding pharmacies have to stop selling tirzepatide Compounded Tirzepatide: Legal & Safe 2026 Compounded Semaglutide & Tirzepatide 2025:

The SURPASS Trials The SURPASS program included multiple phase 3 trials comparing tirzepatide to placebo, semaglutide, and insulin in patients with type 2 diabetes

By the second week after injection, roughly 25% of the original dose remains active, providing continued appetite suppression and metabolic benefits throughout the week

The topline SURPASSCVOT results were first released in a corporate communication, and this subsequent peerreviewed New England Journal of Medicine publication from December 2025 provided the full randomized, doubleblind, eventdriven dataset, including detailed cardiovascular, renal, and safety outcomes monitored for a median of 4 years

Ready to explore your options with a team you can trust